Clinical Trial Update: Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating a triple combination of encorafenib, cetuximab, and nivolumab in patients with microsatellite-stable, BRAFV600E-mutated…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Adenocarcinoma
• Colon Cancer
• Colorectal Cancer
• Rectal Adenocarcinoma
• Rectal Cancer
• Unresectable Colorectal Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• Encorafenib (encorafenib)
• nivolumab (nivolumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: BRAF NP_004324.2:p.V600E, Metastatic Colon Adenocarcinoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING